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RESUMO
Introdução: Analisamos e comparamos os perfis microbiológicos, das infecções intra-abdominais, urinárias, respiratórias e bacterie-
mias, conforme o local de aquisição: da comunidade, com separação das infecções associadas a cuidados de saúde, ou nosocomiais.
Material e Métodos: Coorte prospectiva, desenvolvida num hospital universitário ao longo de um ano. Critério de inclusão: cumprir a 
definição de infecção intra-abdominal, urinária, respiratória ou bacteriemia do Centers for Disease Control.
Resultados: Foram incluídos 1035 doentes. Nas infecções intra-abdominais mais de 25% eram polimicrobianas; a percentagem de 
gram-negativos multi-resistentes foi 38% na comunidade, 50% nas associadas a cuidados de saúde e 57% nas nosocomiais. A E. 
coli foi o agente mais frequente nas infecções urinárias: 69% na comunidade, 56% nas associadas a cuidados de saúde e 26% nas 
nosocomiais; a produção de ESBL foi 10% nas associadas a cuidados de saúde e 3% na comunidade e nosocomiais. Nas infecções 
respiratórias o Streptococcus pneumonia foi o agente mais frequente na comunidade (54%) e o MRSA o mais frequente nas asso-
ciadas a cuidados de saúde (24%) e nosocomiais (24%). Foi encontrada uma associação significativa entre a infecção por MRSA e a 
hospitalização no último ano (OR ajustado = 6,3), instrumentação prévia (OR ajustado = 4,3) e antibioterapia prévia (OR = 5,7); não 
se documentaram casos em doentes sem estes factores de risco. A mortalidade hospitalar foi 10% na infecção da comunidade, 14% 
nas associadas a cuidados de saúde e 19% na nosocomial.
Discussão e Conclusão: Este estudo demonstra que as infecções associadas a cuidados de saúde apresentam perfis microbiológi-
cos diferentes das da comunidade e nosocomiais para cada foco de infecção. Este conhecimento é importante porque as recomenda-
ções existentes para as infecções da comunidade não se aplicam a este grupo de doentes.
Palavras-chave: Infecções Comunitárias Adquiridas; Infecção Hospitalar; Prestação de Cuidados de Saúde; Infecções Respiratórias; 
Infecções Urinárias; Infecções Relacionadas a Cateter.
AbStRACt
Introduction: Microbiological profiles were analysed and compared for intra-abdominal, urinary, respiratory and bloodstream infec-
tions according to place of acquisition: community-acquired, with a separate analysis of healthcare-associated, and hospital-acquired. 
Material and Methods: Prospective cohort study performed at a university tertiary care hospital over 1 year. Inclusion criteria were 
meeting the Centers for Disease Control definition of intra-abdominal, urinary, respiratory and bloodstream infections. 
Results: A total of 1035 patients were included in the study. More than 25% of intra-abdominal infections were polymicrobial; multi-drug 
resistant gram-negatives were 38% in community-acquired, 50% in healthcare-associated and 57% in hospital-acquired. E. coli was 
the most prevalent among urinary infections: 69% in community-acquired, 56% in healthcare-associated and 26% in hospital-acquired; 
ESBL producers’ pathogens were 10% in healthcare-associated and 3% in community-acquired and hospital-acquired. In respira-
tory infections Streptococcus pneumoniae was the most prevalent in community-acquired (54%) and MRSA in healthcare-associated 
(24%) and hospital-acquired (24%). A significant association was found between MRSA respiratory infection and hospitalization in 
the previous year (adjusted OR = 6.3), previous instrumentation (adjusted OR = 4.3) and previous antibiotic therapy (adjusted OR = 
5.7); no cases were documented among patients without risk factors. Hospital mortality rate was 10% in community-acquired, 14% in 
healthcare-associated and 19% in hospital-acquired infection.
Discussion and Conclusion: This study shows that healthcare-associated has a different microbiologic profile than those from com-
munity or hospital acquired for the four main focus of infection. Knowledge of this fact is important because the existing guidelines for 
community-acquired are not entirely applicable for this group of patients.
Keywords: Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Delivery of Health Care; Respiratory Tract Infec-
tions; Urinary Tract Infections; Catheter-Related Infections; Blood-Borne Pathogens.
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INtRODUCtION
 Over the last decade the massive increase in outpatient 
clinical care has led to a new context for the emergence 
of HCAI. This is a new name for the new group of infec-
tions from patients in the community that have a history of 
exposure to the healthcare system and that do not fit the 
nosocomial infection criteria.1 
 In 2002, Deborah Friedman1 proposed a new classifica-
tion for community-acquired bloodstream infections (CAI - 
BSI) in patients with recent hospital admission or exposure 
to significant medical care - healthcare-associated blood-
stream infections (HCAI - BSI) - after a cohort study of 504 
patients with BSI where she noticed significant differences 
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in the microbiological profiles of HCAI, CAI and hospital-
acquired bloodstream infections (HAI - BSI).
 This new concept of HCAI is spreading throughout the 
scientific world and evidence has emerged suggesting that 
this might represent a new group of infections with microbi-
ological and outcome characteristics that are different from 
CAI and HAI.2-5
 The studies performed previously have focused primar-
ily on single focus of infection: pneumonia,3,4,6 BSI2,5,7 or 
urinary (UTI).8 To the best of our knowledge, no study has 
been published concerning intra-abdominal infections (IAI), 
although these are among the three most common infec-
tions that result in hospitalization.9
 The objective of this study is to analyse differences in 
the microbiological profiles and outcomes of the major fo-
cus of infection that drive patients into hospital care: IAI, 
UTI, respiratory and BSI - HCAI, CAI and HAI. Additionally 
independent risk factors for respiratory infection by MRSA 
will be described.
MAtERIAL AND MEtHODS
Study design and patient population
 This prospective cohort study included all consecutive 
adult patients admitted to the intensive care unit (ICU), 
medical, surgical, nephrology and haematology wards of a 
600-bed university, tertiary care hospital from 1st June 2008 
until 31st May 2009. 
 The inclusion criterion was diagnosis of the infection ac-
cording to the Centers for Disease Control (CDC) criteria,10 
in an adult patient (age ≥ 18 years) admitted onto one of 
the previously mentioned wards. Infections were classified 
as CAI, HCAI or HAI, according to the place of acquisition. 
Only the first episode of infection in the current hospital ad-
mission was characterized for each patient. 
 The primary outcome was detailed microbiological char-
acterization of the microbiological profile of IAI, UTI, respira-
tory infections and BSI, according to the place of acquisition, 
including analysis of the prevalence of multi-drug resistant 
(MDR) pathogens. Secondary outcomes are differences in 
hospital length of stay (LOS) and mortality for different focus 
of infection according to the place of acquisition of infection.
 This study was approved by the Institutional Review 
Board of Hospital de Santo António, Oporto Hospital Cen-
tre, Portugal, and informed consent was waived due to the 
observational nature of the study.
Definitions
 CAI was defined as an infection detected within 48 
hours of hospital admission in patients who did not fit the 
criteria for a HCAI. 
 HAI was defined as a localized or systemic condition 
that resulted from an adverse reaction to the presence of 
an infectious agent(s) or its toxin(s), and that occurred 48 
hours or more after hospital admission and was not incubat-
ing at the time of admission.11 Infections in patients recently 
discharged from the hospital within the previous 2-week pe-
riod were also included in this group. 
 HCAI was defined using the same criteria that Deborah 
Friedman used for HCAI - BSI.1 The infection must have 
been present at the time of hospital admission or within 48 
hours of admission in patients that fulfilled any of the follow-
ing criteria:
•	 Received intravenous therapy at home, wound care 
or specialized nursing care through a healthcare agen-
cy, family or friends; or, self-administered intravenous 
medical therapy in the 30 day period before the onset 
of the infection. Patients whose only home therapy was 
oxygen use were excluded.
•	 Attended a hospital or haemodialysis clinic, or re-
ceived intravenous chemotherapy in the previous 30 
days.
•	 Were hospitalized in an acute care hospital for 2 or 
more days in the previous 90 days.
•	 Resided in a nursing home or long-term care facility.
 The CDC definitions were used to define infections at 
different anatomic sites.10 BSI were classified as primary 
or secondary. Primary BSI were defined according to the 
National Nosocomial Infection Surveillance System,12 and 
include intravascular device-associated infections. A sec-
ondary BSI was defined as the presence of an organism 
isolated from a blood culture that was related to an infection 
at another site.10
 MDR organisms were those resistant to one or more 
classes of antimicrobial agents that are recommended as 
first line therapy.13 Enteric gram-negative rods were consid-
ered MDR if they were resistant to amoxicillin-clavulanate, 
piperacillin-tazobactam, carbapenems, aztreonam, fluoro-
quinolones, 3rd generation cephalosporins, aminoglycosides 
or trimethoprim-sulfamethoxazole. Acinectobacter spp and 
Pseudomonas spp were considered MDR if they were re-
sistant to piperacillin-tazobactam, imipenem/meropenem, 
aztreonam, ciprofloxacin, cefepime, ceftazidime, amino-
glycosides or colistin. The presence of ESBL production 
among E. coli and Klebsiella spp strains was screened by 
the automatic analyzer Vitek2 (BioMérieux). It was always 
confirmed by a disk diffusion test that detects synergism 
between the cephalosporins/monobactam and clavulanate. 
If the interpretation of the results was doubtful we also per-
formed Etest®: the combination strains of cefotaxime and 
cefotaxime/clavulanate and ceftazidime and ceftazidime/
clavulanate allows the detection of ESBL whenever the ratio 
antibiotic/antibiotic + inhibitor is equal or above 8. 
 The comorbidities of patients in the study included im-
munosuppression (administration of chemotherapy in the 
12 months prior to hospital admission, either radiation ther-
apy or administration of 0.2 mg/kg/day prednisolone for at 
least 3 months prior to hospital admission, administration of 
1mg/kg/day of prednisolone for 1 week in the 3 months prior 
to hospital admission or infection with human immunodefi-
ciency virus), chronic liver disease,14 chronic heart failure,14 
chronic respiratory disease,14 chronic renal failure (defined 
as the need for chronic renal support or a history of chronic 
renal insufficiency with a serum creatinine level over 2 mg/
dl), haematological disease,15 cancer,15 diabetes mellitus re-
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quiring insulin therapy or oral hypoglycaemic agents before 
the infection and/or atherosclerosis (defined as a previous 
history of a transient ischemic attack, stroke, angina, myo-
cardial infarction or peripheral arterial disease).
 General medical condition was assessed by the Karnof-
sky index.16 A score of lower than 70 implies that the patient 
is unable to perform normal activities or do active work.
 Sepsis and sepsis-related conditions were diagnosed 
according to the criteria proposed by the ACCP/SCCM.17 
For the first day of antibiotic therapy, the acute physiologi-
cal score, SAPS II,15 and the acute organ dysfunction score, 
SOFA,18 were recorded.
 The initial empirical antibiotic treatment was consid-
ered ‘adequate’ if the antibiotic prescribed within the first 24 
hours matched in vitro susceptibility of a pathogen deemed 
to be the likely cause of infection and when the dosage and 
route of administration were appropriate for current medical 
status (focus and severity of infection); only patients with 
positive microbiology were considered in this analysis.
Statistical analysis
 Data were described with medians and inter-quartile 
ranges. Comparisons were performed using Pearson χ2 or 
Fisher’s exact test for categorical variables and the Mann-
Whitney-U-test for continuous variables. 
 Independent risk factors associated with infection by 
MRSA were assessed in respiratory infections, through a 
logistic regression model, with gender, age, Karnovsky in-
dex < 70, severity of infection, SAPS II, total SOFA score, 
hospitalization in the previous year, previous instrumenta-
tion, previous antibiotic therapy, atherosclerosis, diabetes, 
cancer, haematologic disease,  chronic respiratory disease, 
chronic heart failure, chronic renal failure, chronic hepatic 
disease and imunossupression as independent variables. 
Factors found to be significant at the p < 0.05 level in the 
univariate analysis or that were considered clinical impor-
tant were included in the initial model, and forward stepwise 
variable elimination was then performed to develop the final 
model. Model calibration was assessed using the Hosmer-
Lemeshow goodness-of-fit test. Statistical significance was 
defined as p < 0.05. Data were analyzed using SPSS ver-
sion 18 for Windows (SPSS Inc., Chicago, IL, USA).
RESULtS
 During the study period a total of 3733 patients were 
admitted into the wards and assessed: 1035 (28%) met the 
inclusion criteria of having infection according to the CDC 
definitions of infection. Of all patients, 48% (n = 493) were 
diagnosed with CAI, 22% (n = 225) with HCAI and 30% 
(n = 317) with HAI.  
 Among the patients with HCAI: 6 (3%) received intra-
venous therapy, wound care or specialized nursing care 
at home, 95 (42%) attended a hospital or a haemodialysis 
clinic or received intravenous chemotherapy in the previous 
30 days, 98 (44%) were admitted to an acute care hospital 
for 2 or more days in the previous 90 days and 42 (19%) 
resided in a long-term care facility or in a nursing home; 
16 (7%) had more than one.
Table 1 – Patient characteristics, according to place of acquisition of infection 
Patients’ characteristics 
tOtAL 
(n = 1035)
CAI 
(n = 493)
HCAI 
(n = 225)
HAI 
(n = 317)
HCAI vs. CAI 
p value
HCAI vs. HAI 
p value
Male sex, n (%) 506 (49) 236 (48) 108 (48) 162 (51) 0.974* 0.476* 
Age, median (IQR) 68 (52-81) 67 (49-81) 74 (56-83) 67 (53-80) 0.009† 0.004† 
SAPSII, median (IQR) 29 (22-34) 28 (20-34) 30 (24-35) 28 (22-34) 0.039† 0.119†
Total SOFA score 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 0.561† 0.678†
Severity of infection, n (%) 0.117* 0.243*
Infection 281 (27) 126 (26) 69 (31) 86 (27)
Sepsis 364 (35) 178 (36) 73 (32) 113 (36)
Severe sepsis 296 (29) 139 (28) 70 (31) 87 (27)
Septic shock 94 (9) 50 (10) 13 (6) 31 (10)
Previous comorbidities, n (%) 671 (65) 270 (55) 190 (84) 211 (67) < 0.001* < 0.001* 
Chronic hepatic disease, n (%) 22 (2) 11 (2) 7 (3) 4 (1) 0.454‡ 0.214‡ 
Chronic renal disease, n (%) 149 (14) 31 (6) 63 (28) 55 (17) < 0.001* 0.003* 
Chronic heart failure, n (%) 74 (7) 25 (5) 21 (9) 28 (9) 0.031* 0.841* 
Chronic respiratory disease, n (%) 66 (6) 34 (7) 18 (8) 14 (4) 0.597* 0.081* 
Hematologic disease, n (%) 60 (6) 9 (2) 26 (12) 25 (8) < 0.001* 0.149* 
Cancer, n (%) 45 (4) 10 (2) 16 (7) 19 (6) 0.001* 0.602* 
Diabetes, n (%) 204 (20) 91 (19) 53 (24) 60 (19) 0.114* 0.191* 
Atherosclerotic disease, n (%) 242 (23) 101 (21) 67 (30) 74 (23) 0.006* 0.093* 
Immunosuppression, n (%) 198 (19) 66 (13) 71 (32) 84 (27) < 0.001* 0.019* 
Karvosky index < 70, (%) 319 (31) 115 (23) 112 (50) 106 (33) < 0.001* < 0.001* 
Previous antibiotic therapy, n(%) 367 (36) 51 (10) 86 (38) 230 (73) < 0.001* < 0.001* 
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, IQR – Inter-quartile range.
* Pearson Qui-square Test; † Independent samples median test; ‡ Fisher exact test.
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Table 3 – Microbiological profiles of monomicrobial infections, according to place of acquisition of infection.
Positive microbiology 
tOtAL 
(n = 703) 
n (%)
CAI 
(n = 274) 
n (%)
HCAI 
(n = 165)
n (%)
HAI 
(n = 264)  
n (%)
HCAI vs CAI 
p value 
HCAI vs HAI 
p value 
type of microorganism 0.975† 0.849†
Gram negative 384 (55) 163 (60) 90 (55) 131 (50) 
Gram positive 204 (29) 83 (30) 47 (28) 74 (28) 
Fungi 15 (2) 5 (2) 3 (2) 7 (3) 
Polymicrobial 100 (14) 23 (8) 25 (15) 52 (20) 
Pathogen < 0.001† < 0.001†
E. coli 197 (32) 96 (39) 59 (42) 42 (20) 
S. pneumoniae 65 (11) 58 (23) 6 (4) 1 (1) 
Pseudomonas aeruginosa 43 (7) 6 (2) 5 (4) 32 (15) 
MRSA 39 (6) 2 (1) 8 (6) 29 (13) 
MSSA 39 (6) 7 (3) 18 (13) 14 (6) 
Klebsiella pneumoniae 36 (6) 11 (4) 10 (7) 15 (7) 
Proteus mirabilis 22 (3) 9 (4) 4 (3) 9 (4) 
Haemophilus influenzae 18 (3) 16 (7) 1 (1) 1 (1) 
Enterococcus faecalis 16 (2) 6 (2) 2 (1) 8 (4) 
Enterobacter cloacae 13 (2) 3 (1) 1 (1) 9 (4) 
Acinectobacter baumannii 13 (2) 1 (0) 2 (1) 10 (5) 
Enterococcus faecium 13 (2) 0 (0) 4 (3) 9 (4) 
Others 89 (15) 36 (15) 20 (14) 33 (16)
tOtAL monomicrobial 603 (100) 251 (100) 140 (100) 212 (100)
MDR 324 (54%) 80 (32%) 87 (62%) 157 (74%) < 0.001* 0.019*
ESBL 21 (3%) 4 (2%) 11 (8%) 6 (3%) 0.005† 0.023*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, MRSA – Methicillin resistant Staphylococcus aureus, MSSA – Methicillin 
sensitive Staphylococcus aureus.  ESBL - Extended-spectrum beta-lactamases producer. MDR – Multi-drug resistant
*Pearson Qui-square Test, † Fisher exact test.
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 Patients with HCAI were older (74 years) than patients 
with CAI (67 years, p = 0.009) or HAI (67 years, p = 0.004), 
had higher prevalence of previous comorbidities (84% vs 
55% vs 67%, p < 0.001), namely chronic renal disease 
(28% vs 6% vs 17%, p < 0.005), immunossupression (32% 
vs 13% vs 27%, p < 0.005) and more frequently needed 
help in daily activities  (measured by a Karnofsky index of 
less than 70) (20% vs 23% vs 33%, p < 0.05) (Table 1).
 In HCAI the main focus of infection was urinary (45%); 
in CAI, respiratory (50%) and in HAI, intra-abdominal and 
respiratory (25% and 21% respectively). Overall microbiol-
ogy documentation of infection was 68%: 56% in CAI, 73% 
in HCAI and 83% in HAI, (p < 0.05) (Table 2).
 No significant differences were found between the 3 
groups (CAI, HCAI or HAI) regarding type of microorgan-
ism, namely gram-negatives, gram positives or fungi (table 
3), but there was an increase in polymicrobial infection from 
CAI (8%), to HCAI (15%) and HAI (20%), as well as of MDR 
organisms: 32%, 62% and 74% (p < 0.05). The prevalence 
of ESBL producer micro-organisms was significantly higher 
in HCAI (8%), when compared with the other two groups 
(2% in CAI, 3% in HAI, p < 0.005). 
 The overall microbiological profile considering the 12 
most frequent microorganisms according to place of ac-
quisition of infection was also significantly different with: E. 
coli (39%), Streptococcus pneumoniae (23%) and Haemo-
Table 2 – Distribution of focus of infection, according to place of acquisition of infection 
Focus of infection 
tOtAL 
(n = 1035)
n (%)
CAI 
(n = 493)
n (%)
HCAI 
(n = 225)
n (%)
HAI 
(n = 317)
n (%)
HCAI vs. CAI 
p value
HCAI vs. HAI 
p value
Respiratory 419 (40) 244 (50) 70 (31) 105 (33) < 0.001* 0.622*
Urinary 344 (33) 140 (28) 102 (45) 102 (32) < 0.001* 0.002*
Intra-abdominal 213 (21) 104 (21) 31 (14) 78 (25) 0.020* 0.002*
Primary bloodstream infection 57 (6) 4 (1) 21 (9) 32 (10) < 0.001† 0.719†
Other 2 (0) 1 (0) 1 (1) 0 (0) < 0.001† 1.000†
Microbiological confirmation 703 (68) 274 (56) 165 (73) 264 (83) < 0.001* 0.005*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection.
*Pearson Qui-square Test; † Fisher exact test.
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Table 4 – Comparison of the microbiological profiles, according to place of acquisition and focus of infection.
CAI (n = 251) 
n (%)
HCAI (n = 140) 
n (%)
HAI (n = 212) 
n (%)
HCAI vs. CAI 
p value 
HCAI vs. HAI 
p value 
Intra-abdominal infection, 124 patients with microbiologic documentation
45 (100) 23 (100) 56 (100)
     E. coli, 15 (33)      E. coli, 4 (17)      E. coli, 10 (18) 0.015† 0.008†
     Salmonella, 3 (7)      MSSA, 3 (13)      Clostridium difficile, 5 (9)
     Klebsiella pneumoniae, 2 (4)      Bacillus cereus, 2 (9)      Candida albicans, 4 (7)
     MRSA, 4 (7)
     Others,  11 (25)      Others, 8 (35)      Others, 10 (18)
     Polymicrobial, 14 (31)      Polymicrobial, 6 (26)      Polymicrobial, 23 (41) 0.418* 0.280*
     MDR, gram negative, 9 (38)      MDR, gram negative,3 (50)      MDR, gram negative, 8 (57) 0.660† 1.000†
     ESBL producers, 1 (2)      ESBL producers, 1 (4)      ESBL producers, 2 (4) 1.000† 1.000†
Urinary infection, 306 patients with microbiologic documentation
117 (100) 92 (100) 97 (100)
     E. coli, 81 (69)      E. coli, 51 (56)      E. coli, 25 (26) < 0.115† < 0.001†
     Proteus mirabilis, 9 (8)      Klebsiella pneum., 8 (9)      Pseudomonas aeruginosa,12 (12)
     Enterococcus faecalis, 6 (5)      Proteus mirabilis , 4 (4)      Enterococcus faecalis, 8 (8)
     Others, 16 (14)      Others, 14 (15)      Others, 31 (32)
     Polymicrobial, 5 (4)      Polymicrobial, 15 (16)      Polymicrobial, 21 (22) 0.002* 0.270*
     MDR, gram negative, 49 (47)      MDR, gram negative,49 (70)      MDR, gram negative, 43 (69) 0.003* 1.000*
     ESBL producers, 3 (3)      ESBL producers, 9 (10)      ESBL producers, 3 (3) 0.032† 0.134†
Respiratory infection, 215 patients with microbiologic documentation
107 (100) 29 (100) 79 (100)
     S. pneumoniae, 58 (54)      MRSA, 7 (24)      MRSA, 19 (24) < 0.001† 0.042†
     Haemophilus influenza, 14 (13)      S. pneumoniae, 5 (17)      Pseudomonas aeruginosa, 14 (18)
     MSSA, 5 (5)      Pseudomona aeruginosa, 4 (14)      MSSA, 8 (10)
     Acinectobacter baumannii, 8 (10)
     Others, 26 (24)      Others, 9 (31)      Others, 24 (30)
     Polymicrobial, 4 (4)      Polymicrobial, 4 (14)      Polymicrobial, 6 (8) 0.077† 1.000†
     MDR, 11 (10)      MDR,12 (41)      MDR, 45 (57) 0.001* 0.453*
bloodstream infections (primary and secondary), 153 patients with microbiologic documentation
57 (100) 50 (100) 46 (100)
     E. coli, 22 (39)      E. coli, 16 (32)      MRSA, 8 (17) < 0.001† 0.001†
     S. pneumoniae, 17 (30)      MSSA, 13 (26)      E. coli, 4 (9)
     Enterococcus faecium, 4 (9)
     MSSA, 4 (9)
     Pseudomonas aeruginosa, 4 (9)
     Staphylococcus epidermidis, 4 (9)
     Others, 18 (31)      Others, 19 (38)      Others, 14 (30)
     Polymicrobial, 0 (0)      Polymicrobial, 2 (4)      Polymicrobial, 4 (9) 0.422†
     MDR, 17 (30)      MDR, 24 (50)      MDR, 36 (86) 0.073* 0.341*
CAI – community-acquired infection, HCAI – healthcare-associated infection, HAI – hospital acquired infection, MRSA – Methicillin resistant Staphylococcus aureus, MSSA – Methicillin 
sensitive Staphylococcus aureus, MDR – multidrug resistant microorganism.  
*Chi-square test; †Fisher exact test.
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philus influenza (7%) as the most frequent among CAI; E. 
coli (42%), MSSA (13%) and Klesiella pneumoniae (7%) in 
HCAI and E. coli (20%), Pseudomonas aeruginosa (15%) 
and MRSA (13%) in HAI (Table 3).
 In patients with CAI, HCAI or HAI - IAI, the most preva-
lent pathogen was E. coli, followed by Salmonella in CAI, 
MSSA in HCAI and Clostridium difficile in HAI. There was 
a high prevalence (> 25%) of polymicrobial infections inde-
pendently of the place of acquisition of infection (Table 4). 
 Of the 31 patients with IAI (14% of all HCAI): 23 (74%) 
had microbiological confirmation, being 17 (74%) monomi-
crobial and off those 6 (35%) were caused by gram-negative 
bacilli. Among the gram-negative bacilli the resistance rates 
were 33% to ciprofloxacin, 33% to amoxicillin-clavulanate, 
17% to gentamicin and 17% to 3rd generation cephalospor-
ins. No resistance to piperacillin-tazobactam, trimethroprim-
sulfamethoxazole, amikacin or carbapenem was observed. 
In patients with UTI the most prevalent pathogen was also 
E. coli, followed by Proteus mirabilis in CAI, Klebsiella 
pneumoniae in HCAI and Pseudomonas aeruginosa in HAI. 
There was an increasing prevalence of polymicrobial infec-
tions from CAI (4%), to HCAI (16%, p = 0.002) and HAI 
(22%, p = 0.270). The proportion of MDR-gram-negatives 
was also higher in HCAI (70%) and HAI (69%, p = 1.000) 
than in CAI (47%, p = 0.003). In HCAI there was a high-
er prevalence of ESBL producers (10%) than in CAI (3%, 
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p = 0.032) or HAI (3%, p = 0.134) (Table 4). 
 There were 102 patients with UTI (45% of all HCAI); 
off those 92 (90%) had microbiological confirmation being 
77 (84%) monomicrobial. In monomicrobial HCAI - UTI, 70 
(91%) were caused by gram-negative bacilli. Among the 
group of gram-negative bacilli, resistance rates were: 50% 
to trimethroprim-sulfamethoxazole, 49% to ciprofloxacin, 
24% to amoxicillin-clavulanate, 13% to gentamicin, 3% to 
3rd generation cephalosporins, 1% to piperacillin-tazobac-
tam and 1% to carbapenem.  No resistance to amikacin was 
observed. 
 In patients with respiratory infection the most preva-
lent pathogens were Streptococcus pneumoniae and Hae-
mophilus influenza in CAI and MRSA and Pseudomonas 
aeruginosa in HCAI and HAI. Patients with HCAI had a 
higher rate of polymicrobial infections (14%) than those with 
CAI (4%) or HAI (8%) (Table 4).
 A significant association of MRSA respiratory infection 
(n = 26) and hospitalization in the previous year [adjusted 
OR = 6.3; 95% CI (2.3 - 17.0)], previous instrumentation 
[adjusted OR = 4.3; 95% CI (1.5 - 12.8)] and previous anti-
biotic therapy [adjusted OR = 5.7; 95% CI (1.7 - 18.8)] was 
found. No cases of MRSA respiratory infection were docu-
mented in patients without those risk factors.
 In patients with BSI the most prevalent pathogens were 
E. coli and Streptococcus pneumoniae in CAI, E. coli and 
MSSA in HCAI and MRSA, E. coli, Enterococcus faecium, 
MSSA, Pseudomonas aeruginosa and Staphylococcus 
epidermidis in HAI. There was an increasing prevalence of 
polymicrobial infection from 0% in CAI, to 4% in HCAI and 
9% in HAI (Table 4).
 There were 21 (9%) primary HCAI - BSI, all monomi-
crobial, with MSSA accounting for 62%, Enterococcus fae-
cium for 10% and Citrobacter freundii for another 10% of 
all cases. Gram-negative bacilli were present in 4 patients 
(19%). MRSA was the responsible pathogen in only 1 case. 
No fungal or polymicrobial infections were found among this 
group. 
 Out of the CAI, only 4 patients had primary BSI. All infec-
tions were monomicrobial with different pathogens.
In HAI there were 32 episodes (10%) of primary BSI. MRSA 
was the predominant agent (19%), followed by Pseu-
domonas aeruginosa (12%), MSSA (12%) and Staphylo-
coccus epidermidis (12%). Polymicrobial infections were 
present in 2 patients (6%), and fungal infection in 1 patient.
Patients with HCAI respiratory infection had an increased 
rate of inadequate antibiotic therapy (52%) by compari-
son with CAI (5%) and HAI (30%); they also had a signifi-
cantly higher mortality rate (20%) than those with CAI (9%, 
p = 0.011) (Table 5).
 No significant differences in crude hospital mortality 
were observed in the remaining focus of infection (Table 5).
Hospital LOS was higher in HAI when compared to CAI or 
HCAI (Table 5).
DISCUSSION
 This study confirms that healthcare-associated infec-
tions have distinct microbiological profiles when compared 
Table 5 – Hospital length of stay and crude hospital mortality rate, according to focus of infection and place of acquisition.
Intra-abdominal infections total CAI HCAI HAI
HCAI vs. CAI 
p value
HCAI vs. HAI 
p value
Inadequate antibiotic therapy, n (%) 24 (19) 6 (13) 3 (13) 15 (27) 1.000† 0.245†
Hospital LOS (days), median (IQR) 14 (7-25) 8 (5-20) 13 (8-24) 22 (13-33) 0.022‡ 0.154‡
Hospital mortality, n (%) 29 (14) 9 (9) 3 (10) 17 (22) 1.000† 0.177†
Urinary infections
Inadequate antibiotic therapy, n (%) 69 (23) 25 (21) 26 (28) 18 (19) 0.249* 0.115*
Hospital LOS (days), median (IQR) 11 (7-17) 9 (6-13) 9 (6-13) 19 (11-37) 0.923‡ < 0.001‡
Hospital mortality, n (%) 35 (10) 14 (10) 12 (12) 9 (9) 0.662* 0.489*
Respiratory infections
Inadequate antibiotic therapy, n (%) 44 (21) 5 (5) 15 (52) 24 (30) < 0.001* 0.041*
Hospital LOS (days), median (IQR) 11 (8-22) 10 (8-18) 10 (7-13) 21 (24-39) 0.054‡ < 0.001‡
Hospital mortality, n (%) 63 (15) 22 (9) 14 (20) 27 (26) 0.011* 0.382*
bloodstream infections
Inadequate antibiotic therapy, n (%) 26 (17) 6 (11) 7 (14) 13 (28) 0.583* 0.086*
Hospital LOS (days), median (IQR) 15 (9-28) 12 (8-23) 10 (8-16) 30 (22-48) 0.229‡ < 0.001‡
Hospital mortality, n (%) 25 (16) 9 (16) 5 (10) 11 (24) 0.395* 0.068*
All patients included in the study
Inadequate antibiotic therapy, n (%) 148 (21) 37 (14) 45 (27) 66 (25) < 0.001* 0.601*
Hospital LOS (days), median (IQR) 11 (7-22) 10 (7-17) 10 (7-14) 23 (12-39) 0.876‡ < 0.001‡
Hospital mortality, n (%) 138(13) 47 (10) 32 (14) 59 (19) 0.063* 0.173*
LOS – length of stay, IQR – inter-quartile range, *chi-square test, † Fisher exact test, ‡Mann-Whitney-U-Test.
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with CAI and HAI, considering the overall microbiological 
profiles and the rates of resistance. 
 Previous studies have been restricted to respiratory, 
urinary and BSI.2-8,19 Our study broadens the clinical ap-
plication of the new classification of HCAI to include intra-
abdominal infections. The need for studies in this area is 
clearly stated in the 2007 HCAI summit20 where experts 
declare that ‘no studies specifically related to healthcare-
associated infections were identified’ and that ‘future stud-
ies will need to be conduct to examine whether healthcare-
associated IAI should be delineated as a separate category 
of IAI before specific recommendations can be made’. They 
are fundamental for understanding the microbiological pro-
file involved in each focus of infection, according to place 
of acquisition, in order to develop up-to-date recommenda-
tions for adequate initial empirical antibiotic treatment, a 
well-known prognostic factor.3,21 
 In IAI - HCAI, polymicrobial infections played an impor-
tant role as well as MDR gram-negatives. The IDSA guide-
lines for diagnosis and management of complicated intra-
abdominal infection22 recommend an antipseudomonal 
cephalosporin, carbapenem or β-lactam/β-lactamase inhibi-
tor plus metronidazol, for IAI - HCAI. Based in our results 
these recommendations would be appropriate for our group 
of patients. 
 In UTI- HCAI, we found a high rate of MDR gram-nega-
tive bacilli (70%). The HCAI Summit Critical Appraisal20 sug-
gested that serious HCAI due to suspected gram-negative 
bacteria, independently of the site of infection, should be 
treated empirically with dual coverage that includes amino-
glycosides. That broad approach may not be needed in our 
group of patients with UTI and IAI, due to the lower rate of 
resistance to piperacillin-tazobactam observed. The rate of 
ESBL producers is still low (10%), this not justifying empiri-
cal coverage among our patients.
 Our data on respiratory infections provides further evi-
dence for the application of ATS and IDSA recommenda-
tions,20,23 with empirical coverage of Pseudomonas ae-
ruginosa. However regarding MRSA coverage, although 
it was the second more prevalent pathogen in HCAI and 
HAI respiratory infections, it was found only in patients with 
identified risk factors: previous instrumentation, hospital ad-
missions in the previous year or previous antibiotic therapy. 
No MRSA respiratory infections were diagnosed in patients 
without any of those risk factors. So empirical coverage of 
MRSA is only justified in patients with HCAI and previous 
risk factors for infection by this pathogen.
 Regarding BSI clinicians must considerer whether the 
likely bacteremia reflects a primary process or results sec-
ondarily from an infection elsewhere. This distinction is not 
always made in epidemiological studies.1,2,24,25 but it is fun-
damental for initial antibiotic treatment planning. 
 We selected the definition of HCAI that is most frequent-
ly found in the literature.1,5,6 This allowed us to compare our 
results to those of other studies, but this concept is clearly 
an evolving topic.
 The prospective design of this study, with consensual 
definitions in the protocol, the inclusion of different wards of 
the hospital including intensive care and of the four major 
focus of infection with a thorough comparison of those with 
HCAI with those with CAI and HAI, allowed a more clear 
microbiology characterization.
 This study had a thorough data collection made by a 
single trained doctor allowing full completion of all protocols 
with no missing data per item, along with a complete follow 
up of all patients until hospital discharge, minimizing any 
information bias. 
 Despite being a single-centre study, the microbiological 
profile we describe for respiratory HCAI is very similar to the 
one described in the USA.3,19  The microbiological profile 
found in BSI was similar to the descriptions in Canadian,5 
Spanish7 and USA2 studies suggesting that our results 
might be generalized for other settings. 
CONCLUSIONS
 Our results confirm that HCAI have a unique microbio-
logical profile and higher rates of resistance, when com-
pared with CAI and HAI, for the four main focus of infection. 
Failure to recognize this may lead to adverse outcomes as 
a result of an increased risk of treatment failure.
 Physicians need to be aware of this new classification of 
infections for patients from the community that have previ-
ous exposure to the healthcare system for which the exist-
ing guidelines may not apply.
 Further research involving a large number of patients 
from different institutions and geographic areas is warrant-
ed to confirm our findings and evaluate the need to develop 
specific guidelines for this new group of patients.
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